{{item.videoDuration}}
{{item.title}}
{{item.text}}
{{item.videoDuration}}
{{item.title}}
{{item.text}}
Featured - 4 items
The environment in which Pharmaceutical and Life Sciences companies operate locally and globally is increasingly challenging, being driven by a more and more demanding healthcare agenda. The global need for innovative, cost-effective medicines continues to rise whilst regulators, payers, healthcare providers and patients are demanding greater value for money, proven effectiveness of products, more transparency and access to information. To meet these demands companies are seeking ways to improve R&D productivity, increase the efficiency of its operations, rationalise spending on sales and marketing and enhance financial performance.
Committed to India
2:26
Committed to India: Indian Pharma moving to a more
Committed to India: Indian Pharma moving to a more R&D-focused industry
With the fantastic impetus received from the "MakeInIndia" movement, how can Indian Pharmaceutical companies scale towards the "Discover In India" vision?
PwC's Sujay Shetty weighs in along with Sanjeev Krishan, Chairperson, PwC in India.
Reviving India’s API industry: From the viewpoint of the COVID-19 outbreak
In the context of the recent COVID-19 outbreak, PwC has undertaken an independent study to understand the challenges faced by the Indian active pharmaceutical ingredient (API) industry and interventions required to revive the industry. This study highlights the issues faced by Indian API industry and its increasing dependence on China for the import of APIs and KSM. It details how to go about solving drug shortages in the wake of supply chain disruptions caused by COVID- 19 by analysing the stocking situation, cost differentials, and support provided to local industry by the Chinese government in the form of subsidies.
The paper mentions specific measures, both short- and long-term, to revive the industry, reduce the impact of this and future pandemics on our patients and capitalise on the full potential of API manufacturing capabilities.
Reducing dependency: Making India’s API industry self-reliant
PwC's report takes a deeper look into the Production Linked Incentive (PLI) Scheme for the active pharmaceutical ingredient (API) industry announced by the government recently. This scheme is in line with the theme of building an Aatmanirbhar Bharat (self-reliant India). We have analysed import data of APIs and KSMs3 of 53 identified critical APIs to arrive at recommendations towards making the plan robust.
PwC has recommended expanding the scope of the current scheme through the inclusion of exports and existing facilities, backward integration, the inclusion of some critical products and faster clearances. Strengthening bilateral trade and subsidising the cost of production of critical APIs for existing domestic manufacturers will prove to be beneficial for the industry. We have also recommended a few measures aimed at building a conducive ecosystem like granting infrastructure status to the API industry, promoting industry-academia initiatives and supporting research and development (R&D).
Sujay Shetty
Leader
The scheme is a step in the right direction towards making the API industry self-reliant over a period of time. The scheme should ensure that its benefits promote sustainable growth of the API industry by focusing on the industry’s long-term survivability. For the scheme’s success, key elements like scale of operations and backward integration need to be addressed.
How we can help
We work closely with our clients, ranging from small entrepreneurial life science companies to large global corporations. We aim to achieve increased performance by improving the efficiency and effectiveness of a company’s key business operations across the whole Pharmaceutical and Life Sciences value chain from R&D, supply chain and sales and marketing. We also work with clients across a range of corporate functions, including regulatory, compliance, IT, finance, human resources, revenue cycle, operations and M&A strategy.
PwC's trusted consultants and professional advisors across the network, use their wealth of industry-based experience, knowledge and expertise to help our clients evaluate their strategic business options, improve management and control, and identify cost saving initiatives. We develop close working relationships with our clients to understand their operating environment to ensure we deliver solutions to their specific needs.
R&D
Supply Chain
Sales & Marketing
Regulatory Compliance
Our Services
- Manufacturing and supply chain excellence
- Growth strategy and commercial excellence
- Research and development
- People, processes and implementation
- Governance, risk and compliance
- Digital
- Data and analytics
- Cyber security
Manufacturing and supply chain excellence
A combination of regulatory, market, scientific, and technological forces is likely to mean that pharmaceuticals manufacturing and supply chain process will undergo rapid change in the near future. There is a need for companies to more consistently align investment in IT, manufacturing and supply chain with their vision of the manufacturing and supply chain that will be needed in the future. Companies will have to step up their quality and manufacturing compliances and bring in cost and efficiency of supply chain.
We help our clients:
- Quality transformation, FDA remediation and inspection readiness
- Supply chain transformation and ops excellence
- Operations and facilities due diligence
- Manufacturing strategy and footprint expansion
- Strategic sourcing, logistics
- Productivity improvement
- Production and operations
- Integrated planning and post-sales support technology
Growth strategy and commercial excellence
In the current environment of poor product pipelines and broader customer bases, the traditional commercial operations model of driving revenue with ever larger sales forces is no longer sustainable. Rather organisations will evolve to become more efficient and deliver differentiated effective messages tailored to the specific needs of diverse customer segments including patients, insurers, government and physicians, and the changes on product mix.
We help our clients :
- Therapy area entry or growth strategy
- Maximising sales from S&M investments
- Inorganic strategy (M&A, licensing, DD)
- Field force strategy and effectiveness
- Product portfolio prioritisation
- Overseas market entry strategy
- Pricing strategy and market access
- New product launch and brand building
Research and development
As the industry faces a whole host of individual yet challenging issues, it is difficult to see how best to navigate the immediate and long term future. We work closely with our clients to help formulate a new strategy for success and achieve increased performance by improving the efficiency and effectiveness of the company’s R&D operations. Our advisors have a wealth of industry based R&D experience and expertise with a deep understanding of finance, tax, risk management/compliance, IT systems, operations and human resources.
We help our clients :
- R&D centre strategy
- Maximise value from R&D investments
- Optimising technology transfer processes
- R&D quality systems assessment
- Differentiated and super Gx pipeline strategy
- NCE/biologics asset development strategy
- Enhancing throughput and pipeline efficiencies
- Global hub and spoke model for R&D
People, processes and implementation
Pharmaceuticals and life Sciences companies invest heavily in their people. The challenge is to make sure that investment is effective, attracting and retaining people with great skills, and motivating them to do the right things in the right way. By combining our expertise in people strategy and business effectiveness, reward and compensation, employment services, retirement benefits, actuarial, international mobility and transactions, we are able to deliver solutions on all issues relevant to the development, reward and management of employees within pharmaceuticals organisations.
We help our clients :
- Capabilities mapping and plugging gaps
- Streamlining sales, HR, IT processes
- Programme management of strategic initiatives
- Leading significant change efforts
- Organisation structure, roles and RASCI clarity
- Digital strategy implementation
- Implementing review mechanisms/MIS
- Organisation assessment and transformation
Governance, risk and compliance
The pharmaceuticals and life Sciences industries are among the most heavily regulated industries in the world. The regulatory environment is continuously changing in response to the effects of globalisation and harmonisation, outsourcing emerging markets, increasing complexity of disease targets, introduction of new technologies and the rising sophistication and demands of both patients and regulators.
We help our clients :
- Internal Audit
- USFCPA
- USFDA Compliance
- UCPMP /Selling code
- UK Anti Bribery
- Other Compliances
Digital
Technology is an important enabler of business transformation. Businesses need to adopt new behaviours, learn new skills and embrace new ways of working to succeed. As customers rapidly adopt digital, our service offerings are helping our clients respion to their customer's needs and anticipate future ones. Digital is not just about the technologies. Its' about new ways of solving problems, create unique experiences and accelerating business performance..
We partner with our clients through our digital offerings to help determine what success looks like, innovate their business and create new value.
- Digital strategy and engagement
- Digital behaviour - HCP archetypes
- Customer experience strategy
- Patient engagement service design
- User experience and design
- Usability testing
- Digital analytics - Understanding digital channel performance
- Media effectiveness
- Emerging technology scan and implementation
- Innovation accelerator
Data and analytics
PwC Data and Analytics (D&A) practice uses information as a strategic weapon to transform businesses; embeds analytics in operational systems and business processes to help companies realise the true value of their data; brings deep functional knowledge that accelerates the generation of domain-specific insights from information & analytics and employs advanced, well-tested, technologies to address challenging problems for our clients. We have a pool of 500+ D&A consultants, with 100+ specialised in advanced analytics join client engagements, who apply their knowledge to solve specific business challenges.
We help our clients :
- BI and data management strategy, vendor evaluation
- BI on ERP
- Enterprise wide data warehouse implementation
- Financial planning, budgeting and consolidation
- Analytics strategy
- Analytics maturity assessment and benchmarking
- Analytics model implementation
- Analytics competency centre set-up
Cyber security
Our comprehensive cyber security services not only help businesses to assess, build and manage their cyber security capabilities, but also enable them to respond to incidents and crises. We are globally recognised as a leader in cyber security. Internationally, we were ranked as the top professional security consulting services firm in Gartner’s competitive landscape report in 2013.
We help our clients :
- Security strategy and governance
- Security architecture
- Threat and vulnerability management
- Security implementation
- Security as a service
- Identity and access management
- Risk and compliance
- Incident management
Insights
{{filterContent.facetedTitle}}
{{contentList.loadingText}}
{{contentList.loadingText}}
Explore Further
Follow us
Contact us
